Nastech Appoints J. Michael French as Chief Executive Officer and Initiates New Corporate Direction with Name Change to MDRNA

by Joan Trombetti, Writer | June 26, 2008

About Dicer Substrates and Meroduplex Technology

Dicer substrates are oligonucleotides that are slightly longer than standard "RISC" substrates and are processed by the Dicer enzyme into the siRNA strands that activate the RNAi pathway. MDRNA is utilizing the unique characteristics of Dicer substrates to develop novel delivery approaches for safe and effective systemic delivery of RNAi-based therapeutics.

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money

Meroduplex, or "mdRNA", is a next-generation oligonucleotide technology being pioneered and developed by MDRNA, Inc. as a platform approach for the development of potentially safer and more efficacious RNAi-based therapeutics.

About MDRNA, Inc.

MDRNA, Inc. is a biotechnology company developing RNAi-based therapeutics. The company's primary focus is on the safe and effective delivery of MDRNAi and siRNA drug candidates for the treatment of a wide range of human diseases, including inflammation, viral infections, cancer and metabolic disorders. MDRNA will continue to leverage its expertise and capabilities toward innovation in novel and useful RNA-based compositions in order to increase the value proposition of MDRNA to investors and partners. Additional information about MDRNA, Inc. is available at http://www.mdrnainc.com.

Back to HCB News